Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Phase 1

Recruiting

Conditions: Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Undifferentiated Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine
Drug: Mycophenolate Sodium
Biological: Filgrastim
Procedure: Hematopoietic Cell Transplantation
Drug: Mitoxantrone
Drug: Idarubicin
Drug: Mycophenolate Mofetil
Drug: Fludarabine
Radiation: Total-Body Irradiation
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography
Procedure: X-Ray Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2020-05-05

Last Posted Date: 2024-11-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT04375631

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Phase 2

Recruiting

Conditions: Primary Myelofibrosis
Secondary Myelofibrosis

Interventions: Drug: Cyclophosphamide
Drug: JAK Inhibitor
Drug: Fludarabine
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan

First Posted Date: 2020-04-30

Last Posted Date: 2024-07-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04370301

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Phase 2

Withdrawn

Conditions: Refractory Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia

Interventions: Biological: Cytokine induced memory-like NK cells
Procedure: Leukapheresis
Drug: Fludarabine
Drug: Ara-C
Drug: G-CSF
Drug: Interleukin-2

First Posted Date: 2020-04-21

Last Posted Date: 2023-04-04

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT04354025

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Acute Leukemia
Myelodysplastic Syndrome
Secondary Myelofibrosis
Hematologic and Lymphocytic Disorder
Primary Myelofibrosis

Interventions: Drug: Fludarabine
Drug: Itacitinib Adipate
Drug: Melphalan
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Sirolimus
Drug: Tacrolimus

First Posted Date: 2020-04-09

Last Posted Date: 2024-06-27

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 59

Registration Number: NCT04339101

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2

Recruiting

Conditions: Autoimmune Lymphoproliferative
Common Variable Immunodeficiency
Immune System Diseases
Primary T-cell Immunodeficiency Disorders
Lymphoproliferative Disorders

Interventions: Drug: Busulfan test dose
Drug: Fludarabine
Drug: Busulfan
Drug: Alemtuzumab
Radiation: Total body Irradiation
Procedure: Allogeneic HSCT
Drug: Tacrolimus (Tacro)
Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide (Cytoxan)

First Posted Date: 2020-04-09

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT04339777

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Non Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: TC-110 T Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-03-26

Last Posted Date: 2023-03-16

Lead Sponsor: TCR2 Therapeutics

Target Recruit Count: 6

Registration Number: NCT04323657

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1

Completed

Conditions: HER2-positive Gastric Cancer
HER2-positive Metastatic Breast Cancer
Locally Advanced Solid Tumor
Solid Tumor
Metastatic Cancer

Interventions: Drug: ACE1702
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-03-24

Last Posted Date: 2024-12-05

Lead Sponsor: Acepodia Biotech, Inc.

Target Recruit Count: 12

Registration Number: NCT04319757

Locations: 🇺🇸
Northwestern Univeristy, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳
Taipei Veteran General Hospital, Taipei, Taiwan

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Phase 1

Active, not recruiting

Conditions: BPDCN
B-ALL
AML/MDS
T-ALL

Interventions: Drug: CD123-CAR T
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Drug: Rituximab

First Posted Date: 2020-03-24

Last Posted Date: 2024-08-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 32

Registration Number: NCT04318678

Locations: 🇺🇸
St Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Phase 1

Terminated

Conditions: Relapsed/Refractory Large B-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Lenzilumab
Biological: Axicabtagene Ciloleucel

First Posted Date: 2020-03-19

Last Posted Date: 2024-03-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 6

Registration Number: NCT04314843

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Columbia University Medical Center, New York-Presbyterian Hospital, New York, New York, United States

and more 7 locations

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Phase 1

Conditions: CD19-positive ALL

Interventions: Biological: anti-CD19/CD22 CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-03-11

Last Posted Date: 2020-03-11

Lead Sponsor: The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

Target Recruit Count: 20

Registration Number: NCT04303520

Locations: 🇨🇳
Henan Province of TCM, Zhengzhou, Henan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy